DMD.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015a]|
23
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
24 24
25 25
26 26
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
DNAH12.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@wienandGenomicAnalysesFlowsorted2019b]|
23
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@wienandGenomicAnalysesFlowsorted2019]|
24 24
25 25
26 26
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
DNM2.md
... ...
@@ -19,7 +19,7 @@ timeline
19 19
20 20
|Entity|Tier|Description |
21 21
|:------:|:----:|-----------------------------------------|
22
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021b]|
22
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
23 23
24 24
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25 25
DOCK1.md
... ...
@@ -18,7 +18,7 @@ timeline
18 18
19 19
|Entity|Tier|Description |
20 20
|:------:|:----:|-----------------------------------------|
21
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018b]|
21
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
22 22
23 23
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 24
DTX1.md
... ...
@@ -27,9 +27,9 @@ timeline
27 27
|Entity|Tier|Description |
28 28
|:------:|:----:|--------------------------------------|
29 29
|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@gomezUltraDeepSequencingReveals2023]|
30
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiCodingGenomeSplenic2012c]|
30
+|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiCodingGenomeSplenic2012]|
31 31
|![BL](images/icons/BL_tier2.png) |3 | Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
32
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@zhangGeneticHeterogeneityDiffuse2013; @schmitzGeneticsPathogenesisDiffuse2018a; @chapuyMolecularSubtypesDiffuse2018b]|
32
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@zhangGeneticHeterogeneityDiffuse2013; @schmitzGeneticsPathogenesisDiffuse2018; @chapuyMolecularSubtypesDiffuse2018]|
33 33
|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene |
34 34
35 35
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
DTX3L.md
... ...
@@ -23,9 +23,6 @@ timeline
23 23
|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
24 24
25 25
26
-## Mutation incidence in large patient cohorts (GAMBL reanalysis)
27
-
28
-TABLE2
29 26
30 27
## References
31 28
DUSP2.md
... ...
@@ -8,7 +8,7 @@ link-citations: true
8 8
## Overview
9 9
10 10
DUSP2 functions as a negative regulator of MAPK signaling, particularly affecting the ERK1/2 pathway.
11
-DUSP2 mutations have been reported in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), T-cell/histiocyte-rich large B-cell lymphoma (T/HRLBCL)[@schuhmacherJUNBDUSP2SGK12019b; @hartmannHighlyRecurrentMutations2016b] and they are relatively frequent in DLBCL.
11
+DUSP2 mutations have been reported in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), T-cell/histiocyte-rich large B-cell lymphoma (T/HRLBCL)[@schuhmacherJUNBDUSP2SGK12019; @hartmannHighlyRecurrentMutations2016] and they are relatively frequent in DLBCL.
12 12
DUSP2 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) affected by aberrant somatic hypermutation in B-cell lymphomas, which complicates the interpretation of mutations at this locus.
13 13
These mutations are associated with the ST2 genetic subgroup of DLBCL.
14 14
This gene has some recurrent sites of mutations (hot spots).
... ...
@@ -29,8 +29,8 @@ timeline
29 29
30 30
|Entity|Tier|Description |
31 31
|:------:|:----:|--------------------------------------|
32
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@dunsCharacterizationDLBCLPMBL2021b]|
33
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@morinMutationalStructuralAnalysis2013; @lohrDiscoveryPrioritizationSomatic2012a]|
32
+|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@dunsCharacterizationDLBCLPMBL2021]|
33
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@morinMutationalStructuralAnalysis2013; @lohrDiscoveryPrioritizationSomatic2012]|
34 34
|![FL](images/icons/FL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in FL is tenuous |
35 35
36 36
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
E2F2.md
... ...
@@ -18,7 +18,7 @@ timeline
18 18
19 19
|Entity|Tier|Description |
20 20
|:------:|:----:|--------------------------------------|
21
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022b]|
21
+|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
22 22
23 23
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 24
EDNRB.md
... ...
@@ -18,7 +18,7 @@ timeline
18 18
19 19
|Entity|Tier|Description |
20 20
|:------:|:----:|--------------------------------------|
21
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022b]|
21
+|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
22 22
23 23
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 24
EEF1A1.md
... ...
@@ -24,9 +24,9 @@ timeline
24 24
25 25
|Entity|Tier|Description |
26 26
|:------:|:----:|--------------------------------------|
27
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@reichelFlowSortingExome2015a]|
28
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@hubschmannMutationalMechanismsShaping2021b]|
29
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@hubschmannMutationalMechanismsShaping2021b]|
27
+|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@reichelFlowSortingExome2015]|
28
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@hubschmannMutationalMechanismsShaping2021]|
29
+|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@hubschmannMutationalMechanismsShaping2021]|
30 30
31 31
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
32 32
EGR1.md
... ...
@@ -22,9 +22,9 @@ timeline
22 22
23 23
|Entity|Tier|Description|
24 24
|:------:|:----:|--------------------------------------|
25
-|![FL](images/icons/FL_tier2.png)|2|relevance in FL not firmly established[@krysiakRecurrentSomaticMutations2017b]|
26
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012c]|
27
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015a]|
25
+|![FL](images/icons/FL_tier2.png)|2|relevance in FL not firmly established[@krysiakRecurrentSomaticMutations2017]|
26
+|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
27
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
28 28
29 29
30 30
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
EGR2.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012c]|
23
+|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
24 24
25 25
26 26
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
EP300.md
... ...
@@ -6,11 +6,11 @@ link-citations: true
6 6
# EP300
7 7
8 8
## Overview
9
-Mutations in EP300 are significant contributors to the pathogenesis and progression of B-cell lymphomas such as DLBCL and FL.[@pasqualucciInactivatingMutationsAcetyltransferase2011a] This gene has some recurrent sites of mutations (hot spots), which typically impact its HAT domain, a region crucial for acetylating histones and non-histone proteins.[@pasqualucciInactivatingMutationsAcetyltransferase2011a]
9
+Mutations in EP300 are significant contributors to the pathogenesis and progression of B-cell lymphomas such as DLBCL and FL.[@pasqualucciInactivatingMutationsAcetyltransferase2011] This gene has some recurrent sites of mutations (hot spots), which typically impact its HAT domain, a region crucial for acetylating histones and non-histone proteins.[@pasqualucciInactivatingMutationsAcetyltransferase2011]
10 10
11 11
## Experimental Evidence
12 12
EP300 mutations impair histone acetylation, disrupt epigenetic gene regulation. Mutations in CREBBP and EP300 affect a common pathway and have been described as mutually exclusive due to some functional redundancy.[@pasqualucciInactivatingMutationsAcetyltransferase2011a; @veazeyCARM1InhibitionReduces2020b]
13
-Studies using genome-wide CRISPR-Cas9 screens have identified synthetic lethal interactions between CREBBP and EP300, suggesting that targeting one may affect the viability of cells with mutations in the other.[@nieGenomewideCRISPRScreens2021b]
13
+Studies using genome-wide CRISPR-Cas9 screens have identified synthetic lethal interactions between CREBBP and EP300, suggesting that targeting one may affect the viability of cells with mutations in the other.[@nieGenomewideCRISPRScreens2021]
14 14
15 15
## History
16 16
EPHA7.md
... ...
@@ -21,7 +21,7 @@ timeline
21 21
22 22
|Entity|Tier|Description|
23 23
|:------:|:----:|--------------------------------------|
24
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019b]|
24
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
25 25
26 26
27 27
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
ERAP1.md
... ...
@@ -18,7 +18,7 @@ timeline
18 18
19 19
|Entity|Tier|Description |
20 20
|:------:|:----:|--------------------------------------|
21
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022b]|
21
+|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
22 22
23 23
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 24
ETV6.md
... ...
@@ -30,7 +30,7 @@ timeline
30 30
31 31
|Entity|Tier|Description |
32 32
|:------:|:----:|--------------------------|
33
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012a; @albuquerqueEnhancingKnowledgeDiscovery2017a; @reddyGeneticFunctionalDrivers2017]|
33
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012; @albuquerqueEnhancingKnowledgeDiscovery2017; @reddyGeneticFunctionalDrivers2017]|
34 34
35 35
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
36 36
EZH2.md
... ...
@@ -7,16 +7,16 @@ link-citations: true
7 7
8 8
## Overview
9 9
EZH2 encodes a histone methyltransferase that is a component of the polycomb repressive complex 2 (PRC2).
10
-This gene is recurrently mutated in both FL and DLBCL and has a common mutation hot spot (Y646) that affects the SET domain.[@morinSomaticMutationsAltering2010a]
10
+This gene is recurrently mutated in both FL and DLBCL and has a common mutation hot spot (Y646) that affects the SET domain.[@morinSomaticMutationsAltering2010]
11 11
EZH2 mutations are one of the defining features of the EZB genetic subgroup of DLBCL.[@wrightProbabilisticClassificationTool2020]
12 12
Although mutations in EZH2 have been described in some BL patients, they are extremely rare in most BL cohorts that have been sequenced.[@loveGeneticLandscapeMutations2012; @thomasGeneticSubgroupsInform2023]
13 13
14 14
15 15
## Experimental Evidence
16 16
17
-Mutations at the main hotspot and some less common hotspots lead to enhanced methylation by PRC2.[@yapSomaticMutationsEZH22011b]
17
+Mutations at the main hotspot and some less common hotspots lead to enhanced methylation by PRC2.[@yapSomaticMutationsEZH22011]
18 18
A number of small molecule/pharmacologic inhibitors of EZH2 activity have been described.[@garapaty-raoIdentificationEZH2EZH12013; @knutsonSelectiveInhibitionEZH22014] At least one of these, tazemetostat, has shown benefit in FL.[@morinTreatingLymphomaNow2021]
19
-Combination therapies including EZH2 inhibitors are also under exploration for DLBCL patients with mutant EZH2.[@scholzeCombinedEZH2Bcl22020b]
19
+Combination therapies including EZH2 inhibitors are also under exploration for DLBCL patients with mutant EZH2.[@scholzeCombinedEZH2Bcl22020]
20 20
21 21
## History
22 22
```mermaid
... ...
@@ -36,9 +36,9 @@ timeline
36 36
|Entity|Tier|Description |
37 37
|:------:|:----:|--------------------------------------|
38 38
|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene|
39
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@mottokIntegrativeGenomicAnalysis2019b]|
40
-|![DLBCL](images/icons/DLBCL_tier1.png) |1-EE |high-confidence DLBCL gene supported by functional data [@morinSomaticMutationsAltering2010a]|
41
-|![FL](images/icons/FL_tier1.png) |1-EE |high-confidence FL gene supported by functional data [@morinSomaticMutationsAltering2010a]|
39
+|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@mottokIntegrativeGenomicAnalysis2019]|
40
+|![DLBCL](images/icons/DLBCL_tier1.png) |1-EE |high-confidence DLBCL gene supported by functional data [@morinSomaticMutationsAltering2010]|
41
+|![FL](images/icons/FL_tier1.png) |1-EE |high-confidence FL gene supported by functional data [@morinSomaticMutationsAltering2010]|
42 42
|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@loveGeneticLandscapeMutations2012]|
43 43
44 44
FAT1.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@spinaGeneticsNodalMarginal2016b]|
23
+|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@spinaGeneticsNodalMarginal2016]|
24 24
|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@]|
25 25
26 26
FBXO11.md
... ...
@@ -6,7 +6,7 @@ link-citations: true
6 6
# FBXO11
7 7
8 8
## Overview
9
-Somatic mutations in FBXO11 are common in BL[@richterRecurrentMutationID32012a] and appear in a small number of DLBCLs.[@hubschmannMutationalMechanismsShaping2021b]
9
+Somatic mutations in FBXO11 are common in BL[@richterRecurrentMutationID32012] and appear in a small number of DLBCLs.[@hubschmannMutationalMechanismsShaping2021]
10 10
This gene has some recurrent sites of mutations (hot spots). Mutations lead to stabilization of BCL6, an important transcriptional repressor involved in lymphomagenesis.
11 11
These mutations present a potential novel target for therapeutic intervention, particularly through strategies aimed at degrading BCL6 or inhibiting its function.
12 12
... ...
@@ -25,8 +25,8 @@ timeline
25 25
|Entity|Tier|Description |
26 26
|:------:|:----:|--------------------------|
27 27
|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@parryWholeExomeSequencing2013]|
28
-|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene [@richterRecurrentMutationID32012a]|
29
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@hubschmannMutationalMechanismsShaping2021b; @arthurGenomewideDiscoverySomatic2018]|
28
+|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene [@richterRecurrentMutationID32012]|
29
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@hubschmannMutationalMechanismsShaping2021; @arthurGenomewideDiscoverySomatic2018]|
30 30
31 31
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
32 32
FBXW7.md
... ...
@@ -25,7 +25,7 @@ timeline
25 25
26 26
|Entity|Tier|Description |
27 27
|:------:|:----:|--------------------------|
28
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@zhangGeneticHeterogeneityDiffuse2013; @reddyGeneticFunctionalDrivers2017; @hubschmannMutationalMechanismsShaping2021b]|
28
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@zhangGeneticHeterogeneityDiffuse2013; @reddyGeneticFunctionalDrivers2017; @hubschmannMutationalMechanismsShaping2021]|
29 29
30 30
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
31 31
FCRL3.md
... ...
@@ -9,7 +9,7 @@ link-citations: true
9 9
10 10
|Entity|Tier|Description |
11 11
|:------:|:----:|-----------------------------------------|
12
-|![DLBCL](images/icons/DLBCL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous |
12
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous |
13 13
14 14
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
15 15
FOXC1.md
... ...
@@ -19,7 +19,7 @@ timeline
19 19
20 20
|Entity|Tier|Description |
21 21
|:------:|:----:|--------------------------|
22
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@schmitzGeneticsPathogenesisDiffuse2018a]|
22
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@schmitzGeneticsPathogenesisDiffuse2018]|
23 23
24 24
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25 25
FOXO1.md
... ...
@@ -23,7 +23,7 @@ timeline
23 23
|Entity|Tier|Description |
24 24
|:------:|:----:|--------------------------|
25 25
|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene|
26
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@dunsCharacterizationDLBCLPMBL2021b]|
26
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@dunsCharacterizationDLBCLPMBL2021]|
27 27
|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene [@schmitzBurkittLymphomaPathogenesis2012]|
28 28
|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@morinFrequentMutationHistonemodifying2011]|
29 29
|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@morinFrequentMutationHistonemodifying2011]|
FUT5.md
... ...
@@ -17,7 +17,7 @@ timeline
17 17
18 18
|Entity|Tier|Description |
19 19
|:------:|:----:|-----------------------------------------|
20
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018b]|
20
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
21 21
22 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 23
FZR1.md
... ...
@@ -19,7 +19,7 @@ timeline
19 19
20 20
|Entity|Tier|Description |
21 21
|:------:|:----:|--------------------------------------|
22
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021b]|
22
+|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
23 23
24 24
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25 25
GABRA1.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012a]|
23
+|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
24 24
25 25
26 26
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
GABRA2.md
... ...
@@ -17,7 +17,7 @@ timeline
17 17
18 18
|Entity|Tier|Description |
19 19
|:------:|:----:|-----------------------------------------|
20
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018b]|
20
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
21 21
22 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 23
GAK.md
... ...
@@ -19,7 +19,7 @@ timeline
19 19
20 20
|Entity|Tier|Description |
21 21
|:------:|:----:|-----------------------------------------|
22
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021b]|
22
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
23 23
24 24
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25 25
GBP7.md
... ...
@@ -17,7 +17,7 @@ timeline
17 17
18 18
|Entity|Tier|Description |
19 19
|:------:|:----:|--------------------------------------|
20
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023b]|
20
+|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
21 21
22 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 23
GCSAM.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019b]|
23
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
24 24
25 25
26 26
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
GNA13.md
... ...
@@ -23,7 +23,7 @@ timeline
23 23
24 24
|Entity|Tier|Description |
25 25
|:------:|:----:|--------------------------|
26
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@reichelFlowSortingExome2015a]|
26
+|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@reichelFlowSortingExome2015]|
27 27
|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene [@loveGeneticLandscapeMutations2012]|
28 28
|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@morinFrequentMutationHistonemodifying2011]|
29 29
|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@morinFrequentMutationHistonemodifying2011]|
GPC5.md
... ...
@@ -17,7 +17,7 @@ timeline
17 17
18 18
|Entity|Tier|Description |
19 19
|:------:|:----:|-----------------------------------------|
20
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@schmitzGeneticsPathogenesisDiffuse2018a]|
20
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@schmitzGeneticsPathogenesisDiffuse2018]|
21 21
22 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 23
GPR126.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@wenigerMutationsTumorSuppressor2006a]|
23
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@wenigerMutationsTumorSuppressor2006]|
24 24
25 25
26 26
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
GPR98.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016b]|
23
+|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
24 24
25 25
26 26
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
GPS2.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012c]|
23
+|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
24 24
25 25
26 26
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
GRM6.md
... ...
@@ -17,7 +17,7 @@ timeline
17 17
18 18
|Entity|Tier|Description |
19 19
|:------:|:----:|--------------------------------------|
20
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023b]|
20
+|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
21 21
22 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 23
GSG2.md
... ...
@@ -17,7 +17,7 @@ timeline
17 17
18 18
|Entity|Tier|Description |
19 19
|:------:|:----:|-----------------------------------------|
20
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@schmitzGeneticsPathogenesisDiffuse2018a]|
20
+|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@schmitzGeneticsPathogenesisDiffuse2018]|
21 21
22 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 23
H1FOO.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012a]|
23
+|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
24 24
25 25
26 26
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HECW2.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015a]|
23
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
24 24
25 25
26 26
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HELLS.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015a]|
23
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
24 24
25 25
26 26
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HIST1H1B.md
... ...
@@ -22,9 +22,9 @@ timeline
22 22
23 23
|Entity|Tier|Description |
24 24
|:------:|:----:|--------------------------------------|
25
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@sarkozyMutationalLandscapeGray2021a]|
26
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@chapuyMolecularSubtypesDiffuse2018b]|
27
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017b]|
25
+|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@sarkozyMutationalLandscapeGray2021]|
26
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@chapuyMolecularSubtypesDiffuse2018]|
27
+|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
28 28
29 29
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
30 30
HIST1H1D.md
... ...
@@ -26,8 +26,8 @@ timeline
26 26
|:------:|:----:|--------------------------------------|
27 27
|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
28 28
|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
29
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@morinMutationalStructuralAnalysis2013; @chapuyMolecularSubtypesDiffuse2018b]|
30
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017b]|
29
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@morinMutationalStructuralAnalysis2013; @chapuyMolecularSubtypesDiffuse2018]|
30
+|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
31 31
32 32
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
33 33
HIST1H2AC.md
... ...
@@ -22,7 +22,7 @@ timeline
22 22
|Entity|Tier|Description |
23 23
|:------:|:----:|--------------------------|
24 24
|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@morinMutationalStructuralAnalysis2013; @chapuyMolecularSubtypesDiffuse2018b; @hubschmannMutationalMechanismsShaping2021b]|
25
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017b]|
25
+|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
26 26
27 27
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
28 28
HIST1H2AG.md
... ...
@@ -25,7 +25,7 @@ timeline
25 25
26 26
|Entity|Tier|Description |
27 27
|:------:|:----:|-----------------------------------------|
28
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012c]|
28
+|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
29 29
|![BL](images/icons/BL_tier2.png) |3 | Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
30 30
|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established|
31 31
|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene |
HIST1H2AL.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012a]|
23
+|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
24 24
25 25
26 26
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HIST1H2AM.md
... ...
@@ -26,7 +26,7 @@ timeline
26 26
|Entity|Tier|Description |
27 27
|:------:|:----:|--------------------------------------|
28 28
|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene |
29
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017b]|
29
+|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
30 30
|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
31 31
32 32
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HIST1H2BC.md
... ...
@@ -22,9 +22,9 @@ timeline
22 22
23 23
|Entity|Tier|Description |
24 24
|:------:|:----:|--------------------------|
25
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019b]|
26
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012a]|
27
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017b]|
25
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
26
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012]|
27
+|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
28 28
29 29
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
30 30
HIST1H2BD.md
... ...
@@ -17,7 +17,7 @@ timeline
17 17
18 18
|Entity|Tier|Description |
19 19
|:------:|:----:|-----------------------|
20
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@krysiakRecurrentSomaticMutations2017b]|
20
+|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@krysiakRecurrentSomaticMutations2017]|
21 21
22 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 23
HIST1H2BG.md
... ...
@@ -17,7 +17,7 @@ timeline
17 17
18 18
|Entity|Tier|Description |
19 19
|:------:|:----:|-----------------------|
20
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@krysiakRecurrentSomaticMutations2017b]|
20
+|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@krysiakRecurrentSomaticMutations2017]|
21 21
22 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 23
HIST1H2BK.md
... ...
@@ -26,9 +26,9 @@ timeline
26 26
27 27
|Entity|Tier|Description |
28 28
|:------:|:----:|--------------------------------------|
29
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012c]|
29
+|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
30 30
|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
31
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@zhangGeneticHeterogeneityDiffuse2013; @chapuyMolecularSubtypesDiffuse2018b]|
31
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@zhangGeneticHeterogeneityDiffuse2013; @chapuyMolecularSubtypesDiffuse2018]|
32 32
33 33
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
34 34
HIST1H2BM.md
... ...
@@ -17,7 +17,7 @@ timeline
17 17
18 18
|Entity|Tier|Description |
19 19
|:------:|:----:|--------------------------------------|
20
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@krysiakRecurrentSomaticMutations2017b]|
20
+|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@krysiakRecurrentSomaticMutations2017]|
21 21
22 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 23
HIST1H2BO.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012a]|
23
+|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
24 24
25 25
26 26
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HIST1H3B.md
... ...
@@ -18,8 +18,8 @@ timeline
18 18
19 19
|Entity|Tier|Description |
20 20
|:------:|:----:|--------------------------|
21
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015a]|
22
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012a]|
21
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
22
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012]|
23 23
|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene |
24 24
25 25
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HIST1H3G.md
... ...
@@ -17,7 +17,7 @@ timeline
17 17
18 18
|Entity|Tier|Description |
19 19
|:------:|:----:|-----------------------|
20
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@krysiakRecurrentSomaticMutations2017b]|
20
+|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@krysiakRecurrentSomaticMutations2017]|
21 21
22 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 23
HIST1H3I.md
... ...
@@ -19,7 +19,7 @@ timeline
19 19
|Entity|Tier|Description |
20 20
|:------:|:----:|--------------------------------------|
21 21
|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@paneaWholeGenomeLandscape2019]|
22
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@krysiakRecurrentSomaticMutations2017b]|
22
+|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@krysiakRecurrentSomaticMutations2017]|
23 23
24 24
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25 25
HIST1H4E.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description|
22 22
|:------:|:----:|--------------------------------------|
23
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019b]|
23
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
24 24
25 25
26 26
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HIST1H4J.md
... ...
@@ -18,7 +18,7 @@ timeline
18 18
19 19
|Entity|Tier|Description |
20 20
|:------:|:----:|--------------------------------------|
21
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019b]|
21
+|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
22 22
|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@paneaWholeGenomeLandscape2019]|
23 23
24 24
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HIST2H2BE.md
... ...
@@ -20,7 +20,7 @@ timeline
20 20
21 21
|Entity|Tier|Description |
22 22
|:------:|:----:|--------------------------|
23
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@schmitzGeneticsPathogenesisDiffuse2018a]|
23
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@schmitzGeneticsPathogenesisDiffuse2018]|
24 24
25 25
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
26 26
HLA-A.md
... ...
@@ -22,7 +22,7 @@ timeline
22 22
|Entity|Tier|Description |
23 23
|:------:|:----:|--------------------------------------|
24 24
|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@deschGenotypingCirculatingTumor2020]|
25
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@lohrDiscoveryPrioritizationSomatic2012a]|
25
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@lohrDiscoveryPrioritizationSomatic2012]|
26 26
27 27
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
28 28
HLA-B.md
... ...
@@ -21,8 +21,8 @@ timeline
21 21
22 22
|Entity|Tier|Description |
23 23
|:------:|:----:|--------------------------------------|
24
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@wienandGenomicAnalysesFlowsorted2019b]|
25
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@lohrDiscoveryPrioritizationSomatic2012a]|
24
+|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@wienandGenomicAnalysesFlowsorted2019]|
25
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@lohrDiscoveryPrioritizationSomatic2012]|
26 26
|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established|
27 27
28 28
## Mutation incidence in large patient cohorts (GAMBL reanalysis)